Structured Benefit-Risk Assessment of a New Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Individuals Ages 12 Months and Older

Abstract Introduction A favorable benefit-risk balance is required to support licensure of biologics, in keeping with regulatory agencies’ evolving recommendations, including the United States Food and Drugs Administration. We present a structured semi-quantitative benefit-risk analysis of MenACYW-T...

Полное описание

Библиографические подробности

Главные авторы:	David Neveu, Tamala Mallett Moore, Betzana Zambrano, Aiying Chen, Marie-Laure Kürzinger, Lydie Marcelon, Mandeep Singh Dhingra
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Adis, Springer Healthcare 2023-09-01
Серии:	Infectious Diseases and Therapy
Предметы:	Benefit-risk analysis Quadrivalent meningococcal conjugate vaccine MenACYW-TT Immunogenicity Safety
Online-ссылка:	https://doi.org/10.1007/s40121-023-00864-4
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!